盐酸拓扑替康治疗小细胞肺癌Ⅱ期的临床研究

Clinical study of topotecan on the treatment of small cell lung cancer of stage Ⅱ

目的对拓扑替康治疗Ⅱ期小细胞肺癌的效果进行临床分析,观察其疗效和毒性。方法回顾性分析100例符合条件的小细胞肺癌Ⅱ期患者的临床资料,49例使用拓扑替康治疗,连续5d,3周为一个疗程;51例使用拓扑替康加顺铂联合进行治疗,连续5d,3周为一个疗程。结果使用拓扑替康治疗的患者有效率为34.7%,与顺铂联合用药的小细胞肺癌患者有效率为62.7%,主要的毒副作用为骨髓抑制,单独使用拓扑替康治疗的患者中性粒子缺乏率为51.0%血小板下降28.6%;联合用药的患者中性粒子缺乏率为54.9%,血小板下降35.3%。结论拓扑替康为治疗小细胞肺癌较为有效的药物之一,联合用药可提高其药性以及疗效,而拓扑替康的主要毒副不良反应为血液学毒性。

Objective To explore the clinical results of topotecan in treatment of small cell lung cancer and observe the curative effect and toxicity. Methods A retrospective analysis of the clinical data of 100 cases with the small cell lung cancer in our hospital,49 cases were treated with topotecan for five consecutive days,3 weeks as a course,51 cases were treated with topo tecan combined with cis-platinum for five consecutive days,3 weeks as a course. Results The effective rate of topotecan group was 34.7%,the the effective rate of the combination group was 62.7%,the main side effects were bone marrow suppression,the neutral particle lack rate of topotecan group was 51.0%,the rate of decrease of platelet was 28.6%, the neutral particle lack rate of the combination group was 54.9%,the rate of decrease of platelet was 35.3%. Conclusion Topotecan is an effective drug in the treatment of patients with small cell lung cancer,the combination therapy can increase the resistance and the effect,the main toxic adverse reactions of topotecan are hematologic toxicity.